OSE Stock Overview
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OSE Immunotherapeutics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.03 |
| 52 Week High | €9.80 |
| 52 Week Low | €3.12 |
| Beta | 0.90 |
| 11 Month Change | 24.72% |
| 3 Month Change | 37.44% |
| 1 Year Change | 103.61% |
| 33 Year Change | -9.61% |
| 5 Year Change | 132.13% |
| Change since IPO | -13.59% |
Recent News & Updates
Recent updates
Shareholders Will Be Pleased With The Quality of OSE Immunotherapeutics' (EPA:OSE) Earnings
Oct 04
Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?
May 23We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Oct 02We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Apr 30OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be
May 11Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?
May 08Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher
Mar 16How Is OSE Immunotherapeutics' (EPA:OSE) CEO Paid Relative To Peers?
Dec 01Shareholder Returns
| OSE | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -1.3% | 0.8% | -1.6% |
| 1Y | 103.6% | -19.3% | 4.6% |
Return vs Industry: OSE exceeded the French Biotechs industry which returned -19.3% over the past year.
Return vs Market: OSE exceeded the French Market which returned 4.6% over the past year.
Price Volatility
| OSE volatility | |
|---|---|
| OSE Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: OSE's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: OSE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 52 | Nicolas Poirier | www.ose-immuno.com |
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers.
OSE Immunotherapeutics SA Fundamentals Summary
| OSE fundamental statistics | |
|---|---|
| Market cap | €196.43m |
| Earnings (TTM) | €46.03m |
| Revenue (TTM) | €69.92m |
4.3x
P/E Ratio2.8x
P/S RatioIs OSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSE income statement (TTM) | |
|---|---|
| Revenue | €69.92m |
| Cost of Revenue | €0 |
| Gross Profit | €69.92m |
| Other Expenses | €23.88m |
| Earnings | €46.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | 65.84% |
| Debt/Equity Ratio | 49.6% |
How did OSE perform over the long term?
See historical performance and comparison